Compare ZTO & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZTO | SNN |
|---|---|---|
| Founded | 2002 | 1856 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Advertising | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3B | 14.3B |
| IPO Year | 2016 | 1999 |
| Metric | ZTO | SNN |
|---|---|---|
| Price | $23.69 | $35.19 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 4 |
| Target Price | $21.90 | ★ $32.83 |
| AVG Volume (30 Days) | ★ 2.1M | 968.3K |
| Earning Date | 03-17-2026 | 02-24-2026 |
| Dividend Yield | ★ 2.63% | 2.09% |
| EPS Growth | N/A | ★ 59.91 |
| EPS | ★ 1.16 | 0.56 |
| Revenue | ★ $6,673,175,085.00 | $5,944,000,000.00 |
| Revenue This Year | $12.15 | $7.71 |
| Revenue Next Year | $11.36 | $5.23 |
| P/E Ratio | ★ $19.65 | $62.87 |
| Revenue Growth | ★ 13.17 | 5.35 |
| 52 Week Low | $16.34 | $23.91 |
| 52 Week High | $23.20 | $38.79 |
| Indicator | ZTO | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 72.35 | 62.69 |
| Support Level | $21.69 | $33.10 |
| Resistance Level | $22.39 | $34.42 |
| Average True Range (ATR) | 0.45 | 0.56 |
| MACD | 0.09 | 0.14 |
| Stochastic Oscillator | 95.37 | 95.41 |
ZTO Express is China's largest express delivery company by parcel volume, with a volume share of 19.4% in 2024. It operates a network partner model where it provides line-haul transportation and sorting services, while its local network partners provide first-mile pickup and last-mile delivery services under the ZTO brand name. Headquartered in Shanghai, the company was founded in 2002 by Meisong Lai, who remains chair, CEO, and its major shareholder with 78% voting rights as of March 31, 2025. ZTO's strategic shareholder is leading China e-commerce company Alibaba Group with around an 8.9% interest.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.